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Introduction: We compared 2 anti-citrullinated protein antibody (ACPA) assays using a routine patient cohort.
Methods: Two-hundred ninety-ﬁve sera were collected from patients for whom ACPA was ordered and tested
for ACPA by QUANTA Lite® CCP 3 (INOVA Diagnostics, Inc., San Diego) and EliA® CCP (CCP, Phadia, Germany).
Rheumatoid factor (RF) was determined using Quantex RF(II) (Biokit, Spain).
Results: Acceptable qualitative (96.6%, kappa=0.93) and quantitative agreements (Spearman rho=0.77;
pb0.0001) were observed between the two ACPA assays. Nine samples were CCP3+/CCP2− and one sample
was CCP2+/CCP3−. Of the 9 CCP3+/CCP2− patients, 6 (66.7%) had RA, one patient had ankylosing spondylitis,
one osteoarthritis and one psoriatic arthritis. The CCP3−/CCP2+ patient had juvenile RA. At themanufacturer's
cut-offs, the sensitivities and speciﬁcities were 77.3%/98.1% (CCP2), 81.6%/96.8% (CCP3) and 65.2%/89.6% (RF),
respectively. At 98.7% speciﬁcity level, the sensitivities in the total cohort were 59.6% (CCP2) and 69.5% (CCP3)
while the sensitivities in the RF-negative group were 49.0% (CCP2) and 57.1% (CCP3).
In the RF-negative group, sensitivities for patients with a disease duration of ≤5 years were 38.7% (CCP2) and
51.6% (CCP3).
Conclusion: Discrimination between RA and non-RA patients was better using CCP3, most pronounced in
RF-negative RA.© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Anti-citrullinated protein antibodies (ACPAs) are an important
serological marker in the diagnosis of rheumatoid arthritis (RA) [1–3].
Historically, a combination of several serologic markers, including rheu-
matoid factor (RF, a test for anti-IgG autoantibodies), anti-perinuclear
factor (APF) and anti-keratin antibody (AKA), has been used in the
diagnosis of RA [1]. RF is considered a moderately speciﬁc test for RA,
whereas the APF/AKA-indirect immunoﬂuorescence (IIF) based assays
were reported to be highly speciﬁc [1]. APF and AKA assays, however,
were laborious, time consuming and difﬁcult to standardize because
they requiredhumanbuccal cells or rat tissue sections and IIFmicroscopy
[1]. With the discovery in 1998 that the underlying antigen in the APF/
AKA tests contained citrulline [4], the development of novel assays to de-
tect ACPA was facilitated [1]. The following studies conﬁrmed that ACPAy; BiP, Immunoglobulin binding
tio; MCV, mutated citrullinated
d peptide; RU, relative units;
emic lupus erythematosus; SSc,
Old Grove Rd., San Diego, CA
586 9911.
.job@web.de (M. Mahler).
-NC-ND license.are indeed highly speciﬁc for RA and were recently added as one of the
American College of Rheumatology (ACR)/The European League Against
Rheumatism (EULAR) disease classiﬁcation criteria for RA [5,6]. Whereas
the ﬁrst generation of the cyclic citrullinated peptide (CCP) test relied on
a peptide derived from theﬁlaggrin protein, the second- and third gener-
ation CCP (CCP2, CCP3) tests are no longer based on ﬁlaggrin but on pep-
tides speciﬁcally designed and optimized (mimotypes) [7,8] to detect
ACPA, thereby enhancing the presentation efﬁcacy of the citrulline-
containing epitope.
Over the past few years, many studies have evaluated the diagnostic
performance of ACPA assays on a variety of diagnostic platforms [9–14].
A meta-analysis showed that 71.7% of 18,061 RA patients analyzed
in these combined studies were positive in the CCP2 test compared to
only 1% of 4937 healthy controls and 6% of 15,971 non-RA disease
controls [1]. In early RA patients, 61.6% proved to be positive for CCP2
(n=4589) [15].
In conclusion, both sensitivity and speciﬁcity of the CCP2/CCP3 tests
are signiﬁcantly higher than those of the RF test [2]. The lower speciﬁc-
ity of the RF-IgM is due to its occurrence in other systemic autoimmune
rheumatic diseases (SARDs), in a variety of infectious diseases, and even
in a signiﬁcant percentage of the healthy population [1]. Because of the
relatively low pre-test probability of patients routinely tested for RF and
ACPA (about 15%) for having RA, the increased speciﬁcity of ACPA com-
pared to RF gives the ACPA tests a much greater positive predictive
Table 1
Prevalence of anti-CCP2 and anti-CCP3 antibodies in different disease cohorts.
Disease cohort N= CCP2, no. pos (% pos, 95% CI) CCP3, no. pos (% pos, 95% CI) RF, no. pos (% pos, 95% CI)
RA 141 109 (77.3, 69.5–83.9) 115 (81.6, 74.2–87.6) 92 (65.2, 56.8–73.1)
RA (RF negative) 49 24 (49.0, 34.4–63.7) 28 (57.1, 42.2–71.2) N/A
RA (disease duration≤2 years) 34 26 (76.5, 58.8-89.3) 27 (79.4, 62.1-91.3) 20 (58.8, 40.7–75.4)
RA (disease duration≤5 years) 77 54 (70.1, 58.6–80.0) 59 (76.6, 65.6–85.5) 46 (59.7, 47.9–70.8)
RA (RF negative, disease duration≤5 years) 31 12 (38.7, 21.8–57.8) 16 (51.6, 33.1–69.8) N/A
Ankylosing spondylitis 13 0 (0.0) 1 (7.7, 0.2–36.0) 0 (0.0)
Degenerative spine disease 6 0 (0.0) 0 (0.0) 0 (0.0)
Fibromyalgia 6 0 (0.0) 0 (0.0) 1 (16.7, 0.4–64.1)
Osteoarthrosis 47 1 (2.1, 0.1–11.3) 1 (2.1, 0.1–11.3) 7 (14.9, 6.2–28.3)
Polymyalgia rheumatica 20 0 (0.0) 0 (0.0) 0 (0.0)
Psoriasis arthritis 14 0 (0.0) 1 (7.1, 0.2–33.9) 0 (0.0)
CTD 18 1 (5.6, 0.1–27.3) 1 (5.6, 0.1–27.3) 4 (22.2, 6.4–47.6)
Others 30 1 (3.3, 0.1–17.2) 1 (3.3, 0.1–17.2) 4 (13.3, 3.8–30.7)
RA = rheumatoid arthritis; RF = rheumatoid factor; CTD = connective tissue disease (SLE, SSc, PM, UCTD, MCTD); SLE = systemic lupus erythematosus; SSc = systemic sclerosis;
PM = polymyositis; UCTD = undifferentiated connective tissue disease; MCTD = mixed connective tissue disease.
267A. Swart et al. / Clinica Chimica Acta 414 (2012) 266–272value (PPV) and likelihood ratios [16,17]. Bossuyt at al. showed that the
likelihood ratio for RA was 27.7 for ACPA and only 4.8 for RF [17].
Following the success of the CCP test, several alternative methods
for detecting ACPA have been developed, including assays based on
citrullinated proteins instead of peptides, such as mutated citrullinated
vimentin (MCV; Orgentec, Mainz, Germany), ﬁlaggrin (CPA; Genesis,
London, UK) or a viral citrullinated peptide (VCP; VCP1 and VCP2)
[7,18,19]. The limited data and contradictory results from comparative
studies on anti-MCV autoantibodies [20–22] compared to anti-CCP as-
says are inconclusive with respect to the sensitivity and speciﬁcity of
this assay. In addition, several other autoantigens have been suggested
as target of autoantibodies in RA including Ra33 (hnRNP A2) [1,23], ﬁ-
brinogen [1,24], ﬁbronectin [24], alpha-enolase [24], type II collagen,
immunoglobulin binding protein (BiP) [25] and viral citrullinated pep-
tide (VCP) derived from Epstein Barr Virus encoded protein (EBNA-2)
[19]. None of these markers are widely used in routine diagnosis of RA.
Recent studies comparing different types of ACPA assays [16]
showed that, in general, the peptide-based assays have a somewhat
better sensitivity and speciﬁcity than theprotein-based assays. Although
based on the same antigenic peptide, not all CCP2 assays show the same
performance characteristics [9,10]. Among the studies comparing CCP2
and CCP3 based assays, a few reported a higher sensitivity of the anti-
CCP3 peptide assay compared to anti-CCP2 tests [11,12] while other
investigations did not support these conclusions [13]. It has been specu-
lated that the reported higher sensitivity of CCP3 may only be found in
cohorts with early RA, whereas the sensitivity may be similar in groups
with established disease. Jaskowski et al. found that in RF-negative RA
patients anti-CCP3 antibodiesweremore prevalent than anti-CCP2 anti-
bodies [14]. In an effort to clarify these contradictory results we decidedTable 2
Sensitivity and speciﬁcity of CCP2 and CCP3 at different cut-off values and in relation to rh
Group Assay
(cut-off)
Sens
At manufacturer's c/o CCP2 (10.0) 77.3
CCP3 (20.0) 81.6
RF (15.0) 65.2
At same speciﬁcity 98.7% CCP2 (62) 59.6
CCP3 (103.99) 69.5
RF (180.2) 15.6
In RF negative RA (n=49) CCP2 (10.0) 49.0
CCP3 (20.0) 57.1
In RF negative RA (n=49) and at same speciﬁcity 98.7% CCP2 (62) 24.5
CCP3 (103.99) 40.8
In RF negative RA with disease duration≤5 years (n=31) CCP2 (10.0) 38.7
CCP3 (20.0) 51.6
In RF negative RA with disease duration≤5 years (n=31)
and at same speciﬁcity 98.7%
CCP2 (62) 19.4
CCP3 (103.99) 32.2to stratify our RA patient cohort, both according to disease, as well as to
duration and the presence of RF in the serum, evaluating the two ACPA
assays in a setting of the routine patient population.
2. Materials and methods
2.1. Patients and sera
Sera were collected from 295 patients for whom a CCP test was or-
dered. All patients were derived from a single clinical center (Center
for Rheumatic Diseases, Neuss, Germany) and were collected between
January 13th and March 29th 2011. Since the majority of patients
were diagnosed before the new (2010) criteria were published [5],
the diagnosis of RA was homogeneously based on the revised 1987
ACR diagnostic criteria [26]. In our cohort 98/141 (69.5%) of RA patients
are female and 43/141 (30.5%) are male. The mean age and the average
disease duration were 62.3 years (SD 12.0) and 8.5 years (SD 8.8),
respectively. Patient identity was not disclosed and the data was anon-
ymously used in accordance with the latest version of the Helsinki Dec-
laration of human research ethics.
2.2. Immunoassays
ACPAwere determined by QUANTA Lite® CCP3 (INOVA Diagnostics,
Inc., San Diego, CA) and EliA® CCP (Phadia, Freiburg, Germany). Rheu-
matoid factor (RF) was determined using turbidimetry and Quantex
RF(II) (Biokit, Barcelona Spain). Antibodies to CCP3 and RF were deter-
mined in the laboratory of the Clinic for Rheumatic Disease, Neuss, Ger-
many. Automated QUANTA Lite® CCP3 ELISA was carried out on aneumatoid factor and disease duration.
itivity (95% CI) Speciﬁcity (95% CI) LR+/LR− AUC
% (69.5–83.9%) 98.1% (94.4–99.6%) 39.7/0.23 0.891 (0.850–0.932)
% (74.2–87.6%) 96.8% (92.6–98.9%) 25.1/0.19 0.893 (0.850–0.937)
% (56.8–73.1%) 89.6% (83.7–93.9%) 6.28/0.39 0.800 (0.742–0.848)
% (51.0–67.7%) 98.7% (95.4–99.8%) 45.9/0.41 0.891 (0.850–0.932)
% (61.2–77.0%) 98.7% (95.4–99.8%) 53.5/0.31 0.893 (0.850–0.937)
% (10.0–22.7%) 98.7% (95.4–99.8%) 12.1/0.86 0.795 (0.742–0.848)
% (34.4–63.7%) 98.1% (94.4–99.6%) 25.1/0.52 0.739 (0.646–0.833)
% (42.2%–71.2%) 96.8% (92.6–98.9%) 17.6/0.44 0.723 (0.620–0.827)
% (13.3–38.9%) 98.7% (95.4–99.8%) 18.9/0.77 0.739 (0.646–0.833)
% (27.0–55.8%) 98.7% (95.4–99.8%) 31.4/0.60 0.723 (0.620–0.827)
% (21.8–57.8%) 98.1% (94.4–99.6%) 19.9/0.63 0.699 (0.577–0.821)
% (33.1–69.8%) 96.8% (92.6–98.9%) 15.9/0.50 0.680 (0.543–0.818)
% (7.5–37.5%) 98.7% (95.4–99.8%) 14.9/0.82 0.699 (0.577–0.821)
% (16.7–51.4%) 98.7% (95.4–99.8%) 24.8/0.69 0.680 (0.543–0.818)
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Fig. 1. Receiver operating characteristic analysis. A receiver operating characteristic analysis comparing CCP2, CCP3 and rheumatoid factor (RF) was performed. Sensitivities,
speciﬁcities and area under the curve (AUC) values are presented in the ﬁgure. Both ACPA assays showed similar performance characteristics and outperformed RF.
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Fig. 2. Receiver operating characteristic (ROC) analysis in different subpopulations of rheumatoid arthritis (RA) patients. A ROC analysis comparing CCP2 and CCP3 was performed
using different RA subpopulations. a.) with a disease duration of ≤5 years (n=77), b.) with a disease duration of ≤2 years (n=34), c.) rheumatoid factor negative RA patients
(n=49) and d.) rheumatoid factor negative RA patients with a disease duration of≤5 years (n=31). Sensitivities, speciﬁcities and area under the curve (AUC) values are presented
in Table 2. RF negative RA and a disease duration of ≤2 years was not analyzed due to a small sample size. For further information and statistical analysis, see Table 2.
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269A. Swart et al. / Clinica Chimica Acta 414 (2012) 266–272AP22 Speedy instrument (DAS, Rome Italy) as part of the routine diag-
nostic procedure. In addition, sampleswere also tested in a single run to
verify the results and to conﬁrm integrity of samples. Results showed
100% qualitative agreement and Spearman rho was 1.0. EliA® CCP
was performed on a Phadia® 250 instrument at an academic hospital
laboratory in the U.S. All tests were done according to manufacturers'
instructions. Unless stated, cut-off values recommended in the instruc-
tion for usewere applied (EliA® CCP=10 U/ml, QUANTA Lite® CCP3=
20 units). In the following text, EliA® CCP is referred to as CCP2 and
QUANTA Lite® CCP 3 as CCP3 (based on the antigen used).
2.3. Statistical evaluation
Data were statistically evaluated using Analyse-it software (ver
2.03; Analyse-it Software, Ltd., Leeds, UK). Receiver-operating charac-
teristic (ROC) analysis was carried out to analyze the discrimination be-
tween RA patients and controls. Differences between likelihood ratios
were calculated using BDTcomparator as described previously [27,28].
For all statistical methods, a pb0.05 was considered as signiﬁcant.
3. Results
3.1. Anti-CCP2 and anti-CCP3 antibodies in rheumatoid arthritis
At the manufacturers' cut-offs, 109/141 (77.3%) RA patients were
positive for anti-CCP2, 115/141 (81.6%) for anti-CCP3 antibodies0
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assays, the LR(+) increased with increasing titers of anti-citrullinated protein antibodies (A
off 240.9 U). In c.) and d.) the LR for CCP2 c.) and CCP3 d.) in rheumatoid factor negative RA
17.8 at a cut-off of 20 U/ml and 31.2 for CCP3 (cut-off 240.9 U).and 92/141 (65.2%) for RF. In the control groups 3/154 (1.9%) were
positive for anti-CCP2 [1 osteoarthritis (OA), 1 connective tissue disease
(CTD) and 1 non-rheumatic disease], 5/154 (3.2%) for anti-CCP3 anti-
bodies [1 ankylosing spondylitis (AS), 1 OA, 1 CTD, 1 psoriatic arthritis
(PA) and 1 non-rheumatic disease] and 16/154 (10.4%) for RF (see
Table 1). Thus, the sensitivities and speciﬁcities were 77.3% and
98.1% (CCP2), 81.6% and 96.8% (CCP3), and 65.2% and 89.6% (RF), re-
spectively (see Table 2). At a cut-off which yields 98.7% speciﬁcity, the
sensitivities were 59.6% (CCP2), 69.5% (CCP3) and 14.2% (RF). The
area under the curve (AUC) values obtained from ROC analysis were
0.891 for CCP2, 0.893 for CCP3 and 0.800 for RF (Fig. 1). The difference
in the AUC between the CCP2 and CCP3 tests was not statistically signif-
icant (p=0.9002) whereas the difference of both CCP tests to RF was
signiﬁcant (pb0.01).
3.2. Anti-CCP2 and anti-CCP3 antibodies in RF negative RA and disease
duration of ≤5 years
In the RF-negative RA group (n=49), 49.0% of the patient samples
were positive for anti-CCP2 and 57.1% for anti-CCP3 antibodies
(Table 2, Fig. 2). Thus in the RF-negative RA group, the sensitivities
were 49.0% for anti-CCP2 and 57.1% for anti-CCP3 antibodies (Fig. 2c).
In patients with a disease duration of less than or equal to 5 years
(n=77) 54 or 70.1% were positive for anti-CCP2 while 59 or 76.6%
were positive for anti-CCP3 antibodies (Fig. 2a). In RF-negative RA pa-
tients with a disease duration of less or equal to 5 years (n=31), 120
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ere used to calculate the likelihood ratio (LR) for RA at different cut-off values. In both
CPA). For CCP2 the LR(+) reached 51.3 at a cut-off of 388 U/mL and 91.7 for CCP3 (cut-
with a disease duration of ≤5 years is shown. In this cohort the LR(+) for CCP2 reached
270 A. Swart et al. / Clinica Chimica Acta 414 (2012) 266–272or 38.7% of patients were anti-CCP2 and 16 or 51.6%were ACPA positive
by the CCP3 test (Fig. 2d). Conﬁdence intervals are shown in Table 2.
3.3. Likelihood ratios of anti-CCP2 and anti-CCP3 antibodies in different
cohorts in relation to antibody titers
The likelihood ratios for anti-CCP2 and anti-CCP3 antibodies were
calculated at different cut-off values (see Fig. 3). At the cut-off values
recommended by the manufacturers the LR+ for CCP2 was higher
than for CCP3 (39.7 vs. 25.1, p=0.3764). At this cut-off the LR−
was 0.23 (CCP2) and 0.19 (CCP3, pb0.025). However, at higher
thresholds CCP3 was signiﬁcantly more predictive for RA. The highest
LR+ for CCP2 was found at a cut-off of 388 U/mL (LR+=51.3) and
for CCP3 at a cut-off of 240.9 U (LR+=91.7, p=0.1655). At
this cut-off the LR− was 0.67 (CCP2) and 0.47 (CCP3, pb0.0001). At
the same speciﬁcity (98.7%), the LR+/LR− were 45.9/0.41 for CCP2
and 53.5/0.31 for CCP3 (p=0.4761 for LR+, p=0.0018 for LR−;
see Table 2). In the RF negative group (at the recommended cut-off),
the LR+/LR− were 25.1/0.52 for CCP2 and 17.6/0.44 for CCP3
(p=0.4946 for LR+, p=0.0709; see Table 2, Fig. 3). At the same
speciﬁcity (98.7%) in the RF negative group, the LR+/LR− were
18.9/0.77 for CCP2 and 31.4/0.60 for CCP3 (p=0.0688 for LR+,
p=0.0050 for LR−; see Table 2).
3.4. Agreement between anti-CCP2 and anti-CCP3 antibodies
Acceptable qualitative (96.6%, 95% CI 93.9–98.4%; K=0.93, 95%
CI 0.89–0.97) and quantitative agreements (Spearman rho=0.77;
pb0.0001) were observed between the CCP2 and CCP3 assays (see
Table 3). Nine samples were CCP3+/CCP2− and 1 sample was
CCP2+/CCP3−. Of the nine CCP3+/CCP2− patients, 6 or 66.7% had
RA, 1 patient had AS, 1 OA and 1 PA. The CCP3−/CCP2+ patient
had juvenile RA.Table 3
Agreement between CCP2 and CCP3 in different cohorts.
CCP2 Percent agreement
(95% conﬁdence)
Positive Negative Total
All patients (n=295)
CCP3 Positive 111 9a 120 Pos. agree=99.1% (95.1–100.0%)
Negative 1b 174 175 Neg. agree=95.1% (90.0–97.7%)
Total 112 183 295 Total agree=96.6% (93.9–98.4%)
RA patients (n=141)
CCP3 Positive 109 6 115 Pos. agree=100.0% (96.7–100.0%)
Negative 0 26 26 Neg. agree=81.3% (63.6–92.8%)
Total 109 32 141 Total agree=95.7% (91.0–98.4%)
RF negative RA patients (n=49)
CCP3 Positive 24 4 28 Pos. agree=100.0% (85.8–100.0%)
Negative 0 21 21 Neg. agree=84.0% (63.9–95.5%)
Total 24 25 49 Total agree=91.8% (80.4–97.7%)
RF negative RA patients, disease duration≤5 years (n=31)
CCP3 Positive 12 4 16 Pos. agree=100.0% (73.5–100.0%)
Negative 0 15 15 Neg. agree=78.9% (54.4–93.9%)
Total 12 19 31 Total agree=87.1% (70.2–96.4%)
RA patients, disease duration≤2 years (n=34)
CCP3 Positive 26 1 27 Pos. agree=100.0% (86.8–100.0%)
Negative 0 7 7 Neg. agree=87.5% (47.3–99.7%)
Total 26 8 34 Total agree=97.1% (84.7–99.9%)
RA patients, disease duration≤5 years (n=77)
CCP3 Positive 54 5 59 Pos. agree=100.0% (93.4–100.0%)
Negative 0 18 18 Neg. agree=78.3% (56.3–92.5%)
Total 54 23 77 Total agree=93.5% (85.5–97.9%)
a Six patients had RA, 1 OA, 1 CTD and 1 non-rheumatic disease.
b Patient had juvenile RA.4. Discussion
Anti-citrullinated protein antibodies (ACPA) are an important se-
rological marker in the diagnosis of RA [1,2,17,29]. Although several
studies were designed to compare the performance of various assays,
it hitherto remains uncertain as to which test provides the best clini-
cal utility.
Despite intense efforts that have gone into standardizing ACPA
detection [30], signiﬁcant differences persist between ACPA assays
[10]. The CCP2 peptide sequence has been identiﬁed by screening
peptide libraries of extremely high complexity with sera of RA pa-
tients which resulted in a highly immunogenic antigen [8]. In con-
trast, CCP3 was designed by combinatorial peptide engineering and
contains multiple citrullinated epitopes displayed in a conformational
structure to increase epitope exposure and thus immunoreactivity,
especially for early RA (unpublished data). Therefore both peptides
may not contain bona ﬁde autoantigens, but have been proven to
measure RA speciﬁc antibodies (mimotypes) [8]. Recently it has
been shown that the anti-CCP2 titer in early RA is correlated with
the epitope diversity (epitope spreading) [31,32]. These data indicate
that patients with early RA and especially in the prediagnostic phase
have antibodies to only one or very few epitopes. It has been demon-
strated that the source of antigen is the most important variable in
determining the performance characteristics of an ACPA assay [8].
Unfortunately, the sequences and immunological characteristics of
CCP2 and CCP3 have not been published, since they are proprietary
sequences owned by two companies [29]. Therefore it remains spec-
ulative why patients with RF negative RA and disease duration of less
or equal to 5 years preferentially recognize CCP3 over CCP2. However,
the high sensitivity of the CCP3 antigen is highly desirable in view of
the irreversible joint damage and permanent disability that can fol-
low a delayed diagnosis and treatment of RA [1].
The conclusion from one of the more comprehensive evaluations
of the analytical performance and diagnostic utility of ACPAs demon-
strated that the CCP2 and CCP3 assays evaluated in the present study
are among the best commercial ACPA assays [10].
In a recent study [33], these 2 ACPA assays were compared and it
was concluded that the speciﬁcity of CCP2 was superior to that of
CCP3. As their cohort was limited (only 52 patients were positive in
all CCP tests) their discrepant result may be due to low cohort size,
cohort composition and/or the manual performance of the CCP3 ELISA.
In our study setting samples were tested for CCP3 using a controlled
automated procedure and conﬁrmed in a second (batched) testing. In
this setting, the performance difference between CCP3 and CCP2 in the
entire cohortwas non-signiﬁcant. Both studies are based on a retrospec-
tive cross-sectional study design, however, in our study the clinical sta-
tus of patients with discrepant test results was veriﬁed by chart review
after an average of 12 months. Even though no change of diagnosis
had taken place during clinical follow-up in these patients, based on
the high PPV of ACPA it is important to follow up these patients. It has
been found that ACPA can be measured in the serum of many RA pa-
tients up to 10 years before their ﬁrst presentation to a clinician,
predicting the future development of RA [34].
As Bossuyt et al. [17] stated, it is important for the comparison of
diagnostic assays, such as ACPA, to take into account the likelihood
ratio of the test under evaluation. Therefore we also analyzed the like-
lihood ratios of CCP3 and CCP2 in the present study: in our cohort, the
LR+ was highly dependent on the cut-off used. Although at the man-
ufacturers' cut-off values the LR+ of CCP2 was higher than for CCP3,
at higher thresholds CCP3 was signiﬁcantly more predictive for RA
than CCP2. This observation is in line with the 2010 disease classiﬁca-
tion criteria of RA which make high levels of ACPA a classiﬁcation
criterion [5]. However, the different assay performance in disease
prediction underlines the importance that every clinical center evalu-
ates their post-test probability of disease using the type of ACPA assay
used and their own patient cohort. This has become even more
Table 4
Comparison of results of the present study with ﬁndings by Jaskowski et al. [14].
Disease cohort Current study Jaskowski et al. [14]
N= CCP2 CCP3 N= CCP2 CCP3
RA 141 77.3 (69.5–83.9) 81.6 (74.2–87.6) 137 65 (56–73) 76 (68–83)
RA (RF negative) 49 49.0 (34.4–63.7) 57.1 (42.2–71.2) 28 19 (7–39) 35 (17–56)
RA (RF positive) 98 86.7 (78.4–92.7) 88.8 (80.8–94.3) 109 76 (67–84) 85 (77–91)
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more patients in a given population introducing a certain risk of
over-diagnosis and unnecessary treatment with disease-modifying
anti-rheumatic drugs (DMARD) [35]. Our patients were classiﬁed
according to the 1987 ACR classiﬁcation criteria for RA, but also fulﬁlled
the 2010 criteria [5]. Despite the high sensitivity, the 2010 ACR criteria
still miss some RA patients, especially symmetrical seronegative arthri-
tis and limited joint involvement [36]. In agreement with Jaskowski
et al. [14] we found a higher prevalence of anti-CCP3 (57.1%) than
anti-CCP2 antibodies (49.0%) in RF-negative RA patients. Although
both studies used a similar number of RA patients, the number of RF
negative patients was signiﬁcantly higher in our cohort (49 vs. 28)
resulting in large 95% conﬁdence intervals (see Table 4). The most pro-
nounced difference between CCP3 and CCP2, however, was found in
RF-negative RA patients with disease duration less or equal to 5 years.
In this cohort (n=31) the sensitivity of CCP3 was 51.6% compared to
38.7% for CCP2. Interestingly, we found that all 3 non-RA patients with
a CCP3-positive/CCP2-negative result had a recent diagnosis and in-
cluded 1 patient with AS, 1 with OA and 1 with PA. Although the diag-
nosis of these three patients did not change during the observation
period, based on the strong predictive value of ACPA [34], a future de-
velopment of RA cannot be ruled out. We clearly acknowledge that
our cohort is small and such numbers are not signiﬁcant, however
they do show that much broader attempts are needed to demonstrate
test performance differences in this subgroup in a statistically signiﬁ-
cant way, preferentially in a uniform multi-center and prospective de-
sign encompassing different cohort compositions. Studies focusing on
patients with symptoms of ≤3 months [37] are mandatory to analyze
the performance of ACPA assays in early RA.
Even though ACPA have signiﬁcantly improved the diagnosis of RA,
it is unquestionable that novel biomarkers are required for a better di-
agnosis of early and seronegative RA [3]. Recently, such autoantigens
have been described [38,39] which have not yet been transferred into
commercial use. Shi et al. identiﬁed homocitrullin as a key determinant
for the binding of autoantibodies in ACPA-negative RA patients [39].
Somers et al. identiﬁed several novel autoantigens using phage display
technology [38]. The sensitivities of the novel marker antigens varied
between 2% and 29% with speciﬁcities between 95% and 100% and
are expected to further contribute to closing the diagnostic gap in
ACPA/RF negative-RA. Once more diagnostically relevant biomarkers
have been established, modern multiplexing techniques for the simul-
taneous detection of awide spectrumofmarkersmay provide addition-
al beneﬁt in diagnosis as much as in classiﬁcation of RA subtypes.
5. Conclusion
Discrimination between RA and non-RA patients was better using
CCP3, most pronounced in RF-negative RA with a disease duration of
≤5 years.
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